This page collects WhisperX intelligence signals tagged #Health Policy. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The U.S. Department of Health and Human Services has convened a new advisory committee that is raising immediate questions about its composition and focus. Announced by HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz, the 18-member Healthcare Advisory Committee includes a motivational coach and a ve...
The White House is privately circulating draft legislative text for its drug pricing policy to more than a dozen major pharmaceutical companies, signaling a critical push to secure industry backing. This move, confirmed by people familiar with the meetings, represents a concrete step beyond public rhetoric, placing det...
A West Virginia man's death following a protracted battle with his health insurer over doctor-recommended cancer care has directly spurred new state legislation. Six months after the incident, Republican Governor Patrick Morrisey signed a bill intended to curb the harm of insurance denials, a move that places intense s...
The Trump administration is expanding its pressure campaign on drug prices, now targeting smaller pharmaceutical companies with confidential negotiations. According to sources, including a White House official, these new talks offer a critical pathway for smaller firms to pledge lower prices and potentially avoid the l...
A renewed legislative push in Colorado aims to carve out a major exception to the state's drug pricing oversight, potentially shielding a significant category of medicines from future cost controls. For the second time in two years, a bill is advancing that would exempt all orphan drugs—treatments for rare diseases—fro...
President Trump and his administration have consistently targeted health insurance companies with harsh rhetoric, positioning them as profiteers in need of strict control. Yet, a clear pattern has emerged: nearly every major policy decision since his return to the White House has financially benefited the very industry...
The Trump administration may be preparing a significant policy move to expand Medicare coverage for so-called 'breakthrough devices,' a signal that could reshape market access for innovative medical technologies. This potential shift, hinted at by officials, suggests a departure from the current, often restrictive, rei...